- Home
- BB vs SNDX Comparison
BB vs SNDX Comparison
Compare BB & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- SNDX
- Stock Information
- Founded
- BB 1984
- SNDX 2005
- Country
- BB Canada
- SNDX United States
- Employees
- BB N/A
- SNDX N/A
- Industry
- BB
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BB
- SNDX Health Care
- Exchange
- BB Nasdaq
- SNDX Nasdaq
- Market Cap
- BB 1.5B
- SNDX 1.4B
- IPO Year
- BB 1997
- SNDX 2016
- Fundamental
- Price
- BB $3.64
- SNDX $13.08
- Analyst Decision
- BB Buy
- SNDX Strong Buy
- Analyst Count
- BB 6
- SNDX 11
- Target Price
- BB $3.70
- SNDX $37.64
- AVG Volume (30 Days)
- BB 17.1M
- SNDX 2.2M
- Earning Date
- BB 12-19-2024
- SNDX 11-05-2024
- Dividend Yield
- BB N/A
- SNDX N/A
- EPS Growth
- BB N/A
- SNDX N/A
- EPS
- BB N/A
- SNDX N/A
- Revenue
- BB $638,000,000.00
- SNDX $16,000,000.00
- Revenue This Year
- BB N/A
- SNDX N/A
- Revenue Next Year
- BB $7.65
- SNDX N/A
- P/E Ratio
- BB N/A
- SNDX N/A
- Revenue Growth
- BB N/A
- SNDX N/A
- 52 Week Low
- BB $2.01
- SNDX $12.76
- 52 Week High
- BB $3.85
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- BB 73.10
- SNDX 28.91
- Support Level
- BB $2.96
- SNDX $13.26
- Resistance Level
- BB $2.95
- SNDX $14.18
- Average True Range (ATR)
- BB 0.20
- SNDX 0.83
- MACD
- BB 0.06
- SNDX -0.18
- Stochastic Oscillator
- BB 98.40
- SNDX 7.08
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communication for enterprises. The firm provides endpoint management and protection to enterprises, specializing in regulated industries like government, as well as embedded software to the automotive, medical, and industrial markets.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.